Cancer and arthritis share underlying processes.
Ziegler
J
J
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001168:Arthritis / Q000276:immunology* / Q000473:pathology; D000068579:Celecoxib; D002471:Cell Transformation, Neoplastic / Q000276:immunology; D003111:Colonic Polyps / Q000188:drug therapy; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018450:Disease Progression; D004341:Drug Evaluation; D006801:Humans; D007249:Inflammation; D007527:Isoenzymes / Q000502:physiology*; D008565:Membrane Proteins; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors / Q000502:physiology; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000502:physiology; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D011451:Prostaglandin-Endoperoxide Synthases / Q000502:physiology*; D011720:Pyrazoles; D013379:Substrate Specificity; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use; D019714:Tissue Inhibitor of Metalloproteinases / Q000494:pharmacology / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D019714:Tissue Inhibitor of Metalloproteinases; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D008666:Metalloendopeptidases; D000068579:Celecoxib